KRAS · G12C · chr12:25398284 · COSV57014428
Actionability check → repurposing → custom discovery brief → manufacturing. A fixed clinical workflow that keeps every action linked to evidence.
Case ID
X-2201
Variant
KRAS p.Gly12Cys
Non-Small Cell Lung Cancer · OncoKB L1
Candidate rank
Opens the live workspace with a fully worked KRAS G12C demo case.
0.900
Hit@3
0%
False Positives
Open Source
License
Cite this work
Kharel, A. OpenOncology: An Open-Source Framework for Evidence-Based Drug Matching and De Novo Custom Drug Discovery in Precision Oncology. Research Square (2026).
DOI: 10.21203/rs.3.rs-9707913/v1 · Read the preprint →
Goal
Precision oncology already works, if a hospital has genomic sequencing, evidence curators, and a tumor board. Most don't. OpenOncology is the same evidence-based matching logic, open and free — rank a mutation against approved and repurposing candidates, cite the evidence, and say plainly when nothing is actionable yet.
How each case moves forward
VARIANT CALL
Actionability Check
Validate clinical relevance in your cancer context. If not actionable, we state it directly.
DRUG RANK
Repurposed Options
Rank already-approved candidates first — lower cost, lower risk, faster decision.
CUSTOM BRIEF
Custom Discovery Brief
Structure prediction, docking, and lead ranking generated only when repurposing fails.
SYNTHESIS
Manufacture + Funding
Place a synthesis request and launch crowdfunding from the same case in one step.
Vision
Repurposing covers most cases. It won't cover all of them. When a mutation has no approved or repurposing match, OpenOncology escalates to structure prediction and docking, and can route a synthesis request straight into open crowdfunding — so an unmatched mutation becomes a queued discovery problem, not a dead end.
Community
Built solo so far, out in the open. The validation methodology, the bugs found and fixed, and the cases where results came up short are all public. If you work in computational biology or oncology, or want to help expand the holdout cohorts — this needs more hands than one.
What this doesn't do yet
Replace a molecular tumour board or oncologist review.
Guarantee clinical efficacy for any individual patient.
Provide dosing, scheduling, or combination regimen advice.
Claim peer review or regulatory clearance for any candidate.